(AKBA) Akebia Ther - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00972D1054

AKBA: Kidney disease treatments, Anemia therapies, Iron deficiency medications

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for patients with kidney diseases. The companys lead investigational product, Vafseo (vadadustat), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor currently in Phase III trials for treating anemia associated with chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis patients. Akebia also markets Auryxia, a ferric citrate indicated for controlling serum phosphorus levels in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis CKD patients. The companys pipeline includes AKB-9090, a compound targeting critical-care indications, and AKB-10108, which focuses on conditions related to premature birth. Collaborations include a partnership with Mitsubishi Tanabe Pharma Corporation for vadadustat development and commercialization in Japan and other Asian markets, as well as a research and license agreement with Janssen Pharmaceutica NV for hypoxia-inducible factor prolyl hydroxylase-targeted therapies worldwide. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia is committed to advancing treatments for kidney disease and related conditions. Web URL: https://www.akebia.com

Ticker Symbol: AKBA Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Biotechnology

Support: 1.4

Average Volume 20d: 1,969,439 Last Price: 1.83 SMA 20: 2.04 SMA 50: 2.01 SMA 200: 1.56 ATR: 0.09

Market Cap: $392.73M USD P/E: 0.00 P/E Forward: 0.00 P/B: 4.12 P/S: 2.31 RoE: 91.25

3-Month Forecast: Based on the technical and fundamental data, Akebia Therapeutics (AKBA) is expected to face headwinds in the near term. The stock is trading below its SMA 20 and SMA 50, indicating bearish momentum. The high price-to-book ratio of 4.12 suggests elevated valuations relative to book value, which could limit upside potential. However, the positive return on equity (RoE) of 91.25% indicates efficient profitability from equity. The stock may experience volatility within a narrow range, bounded by the identified support level of 1.4. A potential stabilization or recovery could occur if the company reports positive clinical trial data or strengthens its pipeline.

Additional Sources for AKBA Stock

AKBA Stock Overview

Market Cap in USD 369m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Biotechnology
IPO / Inception 2014-03-20

AKBA Stock Ratings

Growth 5y -33.8%
Fundamental 5.96%
Dividend 0.0%
Rel. Strength Industry 78.6
Analysts 4.33/5
Fair Price Momentum 1.80 USD
Fair Price DCF -

AKBA Dividends

No Dividends Paid

AKBA Growth Ratios

Growth Correlation 3m 9.8%
Growth Correlation 12m 62.1%
Growth Correlation 5y -58.9%
CAGR 5y -14.76%
CAGR/Max DD 5y -0.15
Sharpe Ratio 12m -0.05
Alpha 44.88
Beta 2.44
Volatility 68.86%
Current Volume 13249.9k
Average Volume 20d 2392.7k
What is the price of AKBA stocks?
As of March 16, 2025, the stock is trading at USD 2.26 with a total of 13,249,864 shares traded.
Over the past week, the price has changed by +18.95%, over one month by +6.10%, over three months by +22.83% and over the past year by +64.96%.
Is Akebia Ther a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Akebia Ther is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 5.96 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AKBA as of March 2025 is 1.80. This means that AKBA is currently overvalued and has a potential downside of -20.35%.
Is AKBA a buy, sell or hold?
Akebia Ther has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy AKBA.
  • Strong Buy: 1
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for AKBA stock price target?
According to ValueRays Forecast Model, AKBA Akebia Ther will be worth about 2.2 in March 2026. The stock is currently trading at 2.26. This means that the stock has a potential downside of -4.42%.
Issuer Forecast Upside
Wallstreet Target Price 7.8 246.5%
Analysts Target Price 5.5 143.4%
ValueRay Target Price 2.2 -4.4%